![Actuate Therapeutics Inc](/common/images/company/N_ACTU.png)
Actuate Therapeutics is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). We are developing elraglusib (formerly 9-ING-41), a small molecule that is des... Actuate Therapeutics is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). We are developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B. We believe that the blockade of GSK-3B signaling ultimately results in the death of the cancer cells and the regulation of anti-tumor immunity. We have exclusively licensed a portfolio of GSK-3 inhibitors developed in a collaboration between the University of Illinois-Chicago (UIC) and Northwestern University (NU). 詳細を表示
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.92 | -10.8618654073 | 8.47 | 8.61 | 7.13 | 31235 | 7.85995718 | CS |
4 | -1.195 | -13.6649514008 | 8.745 | 11.1261 | 7.13 | 24217 | 9.02042311 | CS |
12 | -1.69 | -18.29004329 | 9.24 | 11.1261 | 6.27 | 48948 | 8.2349667 | CS |
26 | -1.39 | -15.548098434 | 8.94 | 11.1261 | 5.51 | 46915 | 8.14581094 | CS |
52 | 2.55 | 51 | 5 | 11.1261 | 5 | 24285 | 8.16989894 | CS |
156 | 2.55 | 51 | 5 | 11.1261 | 5 | 8019 | 8.16989894 | CS |
260 | 2.55 | 51 | 5 | 11.1261 | 5 | 5495 | 8.16989894 | CS |
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約